Literature DB >> 26436611

Association Between Hospitalization With Community-Acquired Laboratory-Confirmed Influenza Pneumonia and Prior Receipt of Influenza Vaccination.

Carlos G Grijalva1, Yuwei Zhu2, Derek J Williams2, Wesley H Self2, Krow Ampofo3, Andrew T Pavia3, Chris R Stockmann3, Jonathan McCullers4, Sandra R Arnold4, Richard G Wunderink5, Evan J Anderson6, Stephen Lindstrom7, Alicia M Fry7, Ivo M Foppa8, Lyn Finelli7, Anna M Bramley7, Seema Jain7, Marie R Griffin1, Kathryn M Edwards2.   

Abstract

IMPORTANCE: Few studies have evaluated the relationship between influenza vaccination and pneumonia, a serious complication of influenza infection.
OBJECTIVE: To assess the association between influenza vaccination status and hospitalization for community-acquired laboratory-confirmed influenza pneumonia. DESIGN, SETTING, AND PARTICIPANTS: The Etiology of Pneumonia in the Community (EPIC) study was a prospective observational multicenter study of hospitalizations for community-acquired pneumonia conducted from January 2010 through June 2012 at 4 US sites. In this case-control study, we used EPIC data from patients 6 months or older with laboratory-confirmed influenza infection and verified vaccination status during the influenza seasons and excluded patients with recent hospitalization, from chronic care residential facilities, and with severe immunosuppression. Logistic regression was used to calculate odds ratios, comparing the odds of vaccination between influenza-positive (case) and influenza-negative (control) patients with pneumonia, controlling for demographics, comorbidities, season, study site, and timing of disease onset. Vaccine effectiveness was estimated as (1 - adjusted odds ratio) × 100%. EXPOSURE: Influenza vaccination, verified through record review. MAIN OUTCOMES AND MEASURES: Influenza pneumonia, confirmed by real-time reverse-transcription polymerase chain reaction performed on nasal/oropharyngeal swabs.
RESULTS: Overall, 2767 patients hospitalized for pneumonia were eligible for the study; 162 (5.9%) had laboratory-confirmed influenza. Twenty-eight of 162 cases (17%) with influenza-associated pneumonia and 766 of 2605 controls (29%) with influenza-negative pneumonia had been vaccinated. The adjusted odds ratio of prior influenza vaccination between cases and controls was 0.43 (95% CI, 0.28-0.68; estimated vaccine effectiveness, 56.7%; 95% CI, 31.9%-72.5%). CONCLUSIONS AND RELEVANCE: Among children and adults hospitalized with community-acquired pneumonia, those with laboratory-confirmed influenza-associated pneumonia, compared with those with pneumonia not associated with influenza, had lower odds of having received influenza vaccination.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26436611      PMCID: PMC4688454          DOI: 10.1001/jama.2015.12160

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  38 in total

1.  Vaccine Effectiveness Against Laboratory-confirmed Influenza in Healthy Young Children: A Case-Control Study.

Authors:  Heath Kelly; Peter Jacoby; Gabriela A Dixon; Dale Carcione; Simon Williams; Hannah C Moore; David W Smith; Anthony D Keil; Paul Van Buynder; Peter C Richmond
Journal:  Pediatr Infect Dis J       Date:  2011-02       Impact factor: 2.129

2.  Effectiveness of influenza vaccine for preventing laboratory-confirmed influenza hospitalizations in adults, 2011-2012 influenza season.

Authors:  H Keipp Talbot; Yuwei Zhu; Qingxia Chen; John V Williams; Mark G Thompson; Marie R Griffin
Journal:  Clin Infect Dis       Date:  2013-02-28       Impact factor: 9.079

Review 3.  Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis.

Authors:  Michael T Osterholm; Nicholas S Kelley; Alfred Sommer; Edward A Belongia
Journal:  Lancet Infect Dis       Date:  2011-10-25       Impact factor: 25.071

4.  Live attenuated versus inactivated influenza vaccine in infants and young children.

Authors:  Robert B Belshe; Kathryn M Edwards; Timo Vesikari; Steven V Black; Robert E Walker; Micki Hultquist; George Kemble; Edward M Connor
Journal:  N Engl J Med       Date:  2007-02-15       Impact factor: 91.245

5.  Community-acquired pneumonia requiring hospitalization among U.S. children.

Authors:  Seema Jain; Derek J Williams; Sandra R Arnold; Krow Ampofo; Anna M Bramley; Carrie Reed; Chris Stockmann; Evan J Anderson; Carlos G Grijalva; Wesley H Self; Yuwei Zhu; Anami Patel; Weston Hymas; James D Chappell; Robert A Kaufman; J Herman Kan; David Dansie; Noel Lenny; David R Hillyard; Lia M Haynes; Min Levine; Stephen Lindstrom; Jonas M Winchell; Jacqueline M Katz; Dean Erdman; Eileen Schneider; Lauri A Hicks; Richard G Wunderink; Kathryn M Edwards; Andrew T Pavia; Jonathan A McCullers; Lyn Finelli
Journal:  N Engl J Med       Date:  2015-02-26       Impact factor: 91.245

6.  The test-negative design for estimating influenza vaccine effectiveness.

Authors:  Michael L Jackson; Jennifer C Nelson
Journal:  Vaccine       Date:  2013-03-13       Impact factor: 3.641

7.  Influenza vaccine effectiveness in preventing outpatient, inpatient, and severe cases of laboratory-confirmed influenza.

Authors:  Jesús Castilla; Pere Godoy; Angela Domínguez; Iván Martínez-Baz; Jenaro Astray; Vicente Martín; Miguel Delgado-Rodríguez; Maretva Baricot; Nuria Soldevila; José María Mayoral; José María Quintana; Juan Carlos Galán; Ady Castro; Fernando González-Candelas; Olatz Garín; Marc Saez; Sonia Tamames; Tomás Pumarola
Journal:  Clin Infect Dis       Date:  2013-03-26       Impact factor: 9.079

8.  Vaccine effectiveness for laboratory-confirmed influenza in children 6-59 months of age, 2005-2007.

Authors:  Mary Allen Staat; Marie R Griffin; Stephanie Donauer; Kathryn M Edwards; Peter G Szilagyi; Geoffrey A Weinberg; Caroline B Hall; Mila M Prill; Sandra S Chaves; Carolyn B Bridges; Katherine A Poehling; Gerry Fairbrother
Journal:  Vaccine       Date:  2011-09-21       Impact factor: 3.641

Review 9.  Influenza vaccination for immunocompromised patients: summary of a systematic review and meta-analysis.

Authors:  Charles R Beck; Bruce C McKenzie; Ahmed B Hashim; Rebecca C Harris; Arina Zanuzdana; Gabriel Agboado; Elizabeth Orton; Laura Béchard-Evans; Gemma Morgan; Charlotte Stevenson; Rachel Weston; Mitsuru Mukaigawara; Joanne Enstone; Glenda Augustine; Mobasher Butt; Sophie Kim; Richard Puleston; Girija Dabke; Robert Howard; Julie O'Boyle; Mary O'Brien; Lauren Ahyow; Helene Denness; Siobhan Farmer; Jose Figureroa; Paul Fisher; Felix Greaves; Munib Haroon; Sophie Haroon; Caroline Hird; Rachel Isba; David A Ishola; Marko Kerac; Vivienne Parish; Jonathan Roberts; Julia Rosser; Sarah Theaker; Dean Wallace; Neil Wigglesworth; Liz Lingard; Yana Vinogradova; Hiroshi Horiuchi; Javier Peñalver; Jonathan S Nguyen-Van-Tam
Journal:  Influenza Other Respir Viruses       Date:  2013-09       Impact factor: 4.380

10.  Further evidence for bias in observational studies of influenza vaccine effectiveness: the 2009 influenza A(H1N1) pandemic.

Authors:  Michael L Jackson; Onchee Yu; Jennifer C Nelson; Allison Naleway; Edward A Belongia; Roger Baxter; Komal Narwaney; Steven J Jacobsen; David K Shay; Lisa A Jackson
Journal:  Am J Epidemiol       Date:  2013-08-26       Impact factor: 4.897

View more
  38 in total

1.  The PA Endonuclease Inhibitor RO-7 Protects Mice from Lethal Challenge with Influenza A or B Viruses.

Authors:  Jeremy C Jones; Bindumadhav M Marathe; Peter Vogel; Rodolfo Gasser; Isabel Najera; Elena A Govorkova
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

2.  Influenza vaccination and 1-year risk of myocardial infarction, stroke, heart failure, pneumonia, and mortality among intensive care unit survivors aged 65 years or older: a nationwide population-based cohort study.

Authors:  Christian Fynbo Christiansen; Reimar Wernich Thomsen; Morten Schmidt; Lars Pedersen; Henrik Toft Sørensen
Journal:  Intensive Care Med       Date:  2019-06-11       Impact factor: 17.440

Review 3.  Effects of influenza immunization on pneumonia in the elderly.

Authors:  Jung Yeon Heo; Joon Young Song; Ji Yun Noh; Min Joo Choi; Jin Gu Yoon; Saem Na Lee; Hee Jin Cheong; Woo Joo Kim
Journal:  Hum Vaccin Immunother       Date:  2017-12-19       Impact factor: 3.452

4.  Outcomes of Immunocompromised Adults Hospitalized With Laboratory-confirmed Influenza in the United States, 2011-2015.

Authors:  Jennifer P Collins; Angela P Campbell; Kyle Openo; Monica M Farley; Charisse Nitura Cummings; Mary Hill; William Schaffner; Mary Lou Lindegren; Ann Thomas; Laurie Billing; Nancy Bennett; Nancy Spina; Marisa Bargsten; Ruth Lynfield; Seth Eckel; Patricia Ryan; Kimberly Yousey-Hindes; Rachel Herlihy; Pam Daily Kirley; Shikha Garg; Evan J Anderson
Journal:  Clin Infect Dis       Date:  2020-05-06       Impact factor: 9.079

Review 5.  Influenza.

Authors:  Timothy M Uyeki
Journal:  Ann Intern Med       Date:  2017-09-05       Impact factor: 25.391

6.  Assessment of Virus Interference in a Test-negative Study of Influenza Vaccine Effectiveness.

Authors:  Shuo Feng; Ashley L Fowlkes; Andrea Steffens; Lyn Finelli; Benjamin J Cowling
Journal:  Epidemiology       Date:  2017-07       Impact factor: 4.822

7.  The Use of Test-negative Controls to Monitor Vaccine Effectiveness: A Systematic Review of Methodology.

Authors:  Huiying Chua; Shuo Feng; Joseph A Lewnard; Sheena G Sullivan; Christopher C Blyth; Marc Lipsitch; Benjamin J Cowling
Journal:  Epidemiology       Date:  2020-01       Impact factor: 4.822

8.  Engineered Small-Molecule Control of Influenza A Virus Replication.

Authors:  Elizabeth J Fay; Stephanie L Aron; Ian A Stone; Barbara M Waring; Richard K Plemper; Ryan A Langlois
Journal:  J Virol       Date:  2018-12-10       Impact factor: 5.103

9.  Cost-effectiveness of Strategies for Offering Influenza Vaccine in the Pediatric Emergency Department.

Authors:  Rebecca J Hart; Michelle D Stevenson; Michael J Smith; A Scott LaJoie; Keith Cross
Journal:  JAMA Pediatr       Date:  2018-01-02       Impact factor: 16.193

Review 10.  Integrative Physiology of Pneumonia.

Authors:  Lee J Quinton; Allan J Walkey; Joseph P Mizgerd
Journal:  Physiol Rev       Date:  2018-07-01       Impact factor: 37.312

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.